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Background: Yes-associated protein 1 (YAP 1), the nuclear effector of the Hippo pathway, is a key regulator of
organ size and a candidate human oncogene in multiple tumors. However, the expression dynamics of YAP 1 in
urothelial carcinoma of the bladder (UCB) and its clinical/prognostic significance are unclear.
Methods: In this study, the methods of quantitative real-time polymerase chain reaction (qRT-PCR), Western
blotting and immunohistochemistry (IHC) were utilized to investigate mRNA/ protein expression of YAP 1 in UCBs.
Spearman’s rank correlation, Kaplan-Meier plots and Cox proportional hazards regression model were used to
analyze the data.
Results: Up-regulated expression of YAP 1 mRNA and protein was observed in the majority of UCBs by qRT-PCR
and Western blotting, when compared with their paired normal bladder tissues. By IHC, positive expression of YAP
1 was examined in 113/213 (53.1%) of UCBs and in 6/86 (7.0%) of normal bladder specimens tissues. Positive
expression of YAP 1 was correlated with poorer differentiation, higher T classification and higher N classification
(P < 0.05). In univariate survival analysis, a significant association between positive expression of YAP 1 and
shortened patients’ survival was found (P < 0.001). In different subsets of UCB patients, YAP 1 expression was also a
prognostic indicator in patients with grade 2 (P = 0.005) or grade 3 (P = 0.046) UCB, and in patients in pT1
(P = 0.013), pT2-4 (P = 0.002), pN- (P < 0.001) or pT2-4/pN- (P = 0.004) stage. Importantly, YAP 1 expression
(P = 0.003) together with pT and pN status (P< 0.05) provided significant independent prognostic parameters in
multivariate analysis.
Conclusions: Our findings provide evidences that positive expression of YAP 1 in UCB may be important in the
acquisition of an aggressive phenotype, and it is an independent biomarker for poor prognosis of patients with UCB.
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Bladder cancer is one of the most lethal urological ma-
lignant tumors worldwide [1]. Urothelial carcinoma of
the bladder (UCB) is the most common histological sub-
type of bladder cancer. Overall, 70% of bladder tumors
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reproduction in any medium, provided the orthe remainder present as muscle-invasive disease [2]. To
date, the best established and routinely used clinical
markers to predict UCBs prognosis are pTNM stage and
tumor differentiation [3]. However, the prognosis of UCB
patients with disease of the same clinical stage often differs
substantially even after surgical resection, and this large
variation is mostly unexplained. Thus, a large amount of
investigations on UCB have focused on the discovery of
specific molecular markers that could serve as reliable
prognostic factors. To date, however, the search for spe-
cific molecules in UCB cells that have clinical/prognostic
value remains substantially limited.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Correlation between YAP 1 expression and











≦62b 111 54(48.6) 57(51.4)
>62 102 46(45.1) 56(54.9)
Gender 0.450
Male 183 84(45.9) 99(54.1)
Female 30 16(53.3) 14(46.7)
Histological grade 0.001
G1 77 49(63.6) 28(36.4)
G2 69 29(42.0) 40(58.0)
G3 67 22(32.8) 45(67.2)
pT classification 0.010
pTa/pTis 89 52(58.4) 37(41.6)
pT1 42 19(45.2) 23(54.8)
pT2-4 82 29(35.4) 53(64.6)
pN classification 0.028
pN- 195 96(49.2) 99(50.8)
pN+ 18 4(22.2) 14(77.8)
Tumor size (cm) 0.113
≦2.4c 107 56(52.3) 51(47.7)
>2.4 106 44(41.5) 62(58.5)
Tumor multiplicity 0.561
Unifocal 102 50(49.0) 52(51.0)
Multifocal 111 50(45.0) 61(55.0)
aChi-square test. bmedian age. cmean size. UCB: urothelial carcinoma of
the bladder.
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phosphorprotein, is one of the transcription co-activator
which is regulated by the Hippo tumor suppressor path-
way [4-8]. YAP 1 was originally identified because of its
interaction with the Src family tyrosine kinase Yes [9,10].
Recently, YAP 1 has been suggested to be a candidate
oncogene [11-13], and it was found to be elevated in sev-
eral types of cancers including liver, colon, prostate, ovar-
ian, and breast cancers [14-16]. In addition, it was
reported that transgenic mice with liver-specific YAP 1
overexpression showed a dramatic increase in liver size
and eventually developed tumors [17,18]. To date, how-
ever, abnormalities in YAP 1 and their clinicopathologic/
prognostic implication in UCBs have not been explored.
In this study, quantitative real-time polymerase chain re-
action (qRT-PCR), western blotting, immunohistochemis-
try (IHC) and tissue microarray (TMA) were utilized to
examine the expression dynamics of YAP 1 in a cohort of
UCB and normal bladder tissues. In addition, the correl-
ation between expression of YAP 1 and cell proliferation
levels in UCB tissue was analyzed using the Ki-67 assess-
ment marker.
Methods
Patients and primary UCB samples
For qRT-PCR and western blot analysis, we collected 14
paired fresh UCBs and normal tissue samples from patients
who underwent surgery between October 2011 and April
2012. In addition, a cohort of 213 formalin-fixed, paraffin–
embedded tissues of UCBs diagnosed between 2002 and
2007 at the Department of Pathology and Urology, Cancer
Center and the First Affiliated Hospital, Sun Yat-sen Uni-
versity (Guangzhou, China) was retrieved. The cases se-
lected were based on distinctive pathologic diagnosis of
UCB, undergoing curative resection for tumor without pre-
operative chemotherapy and radiotherapy, and availability
of resection tissue and follow-up data. The disease stage of
each patient was classified or reclassified according to the
2002 AJCC staging system [19]. The 213 patients included
183 males and 30 females aged from 20 to 89 years (me-
dian, 62 years). The average follow-up time was 86.36
months (range, 56.0 to 120.0 months). Among these pa-
tients, 89 underwent radical cystectomy (RC) and 124
underwent transurethral resection of bladder tumor
(TURBT). After TURBT, 50 mg THP was used in
intravesical therapy as weekly intravesical injection
beginning within 24 hours after surgery. The clinico-
pathological characteristics of these 213 patients are
summarized in Table 1. The patients’ consent was
obtained for the use of the tissue samples and records,
and the study protocol was approved and permission
for use of the clinical data was given by the Institutional
Research Ethics Committee of Sun Yat-Sen University
Cancer Center.qRT-PCR analysis
Total RNA was isolated from the 14 pairs of UCB tis-
sue and normal bladder tissue using TRIZOL reagent
(Invitrogen, Carlsbad, CA). RNA was reverse-transcribed
using SuperScript First Strand cDNA System (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instruc-
tions. The YAP 1 sense primer was 5′-CGCTCTTCAAC
GCCGTCA-3′, and the antisense primer was 5′-AGTAC
TGGCCTGTCGGGAGT-3′. For the β-actin gene, the
sense primer was 5′-ATAGCACAGCCTGGATAGCAA
CGTAC-3′, and the antisense primer was 5′-CACCTT
CTACAATGAGCTGCGTGTG-3′. qRT-PCR was done
using SYBR Green PCR master mix (Applied Biosystems)
in a total volume of 20 μl on the 7900HT fast Real-time
PCR system (Applied Biosystems) as follows: 50°C for 2
min, 95°C for 10 min, 40 cycles of 95°Cfor 15 s, and 60°C
for 60 s. A dissociation procedure was performed to gen-
erate a melting curve for confirmation of amplification
specificity. β-actin was used as the reference gene. The
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asΔCt =Ctgene- Ctreference, and the fold change of gene
expression was calculated by the 2-ΔΔCt Method. Ex-
periments were repeated in triplicate.
Western blot analysis
Total proteins from the 14 pairs of UCB tissues and nor-
mal bladder tissues were extracted with 1× SDS sample
buffer [62.5 mmol/L Tris–HCl (pH 6.8), 2% SDS, 10%
glycerol, and 5% 2-mercaptoethanol], and 30 μg of each
protein was electrophoretically separated on 12% SDS
polyacrylamide gels, and transferred to polyvinylidene
difluoride membranes (Millipore). Mouse monoclonal
anti-YAP 1(1:300, Upstate Biotechnology, Lake Placid,
NY) and anti-mouse (1:2000, Santa Cruz Biotechnology,
Santa Cruz, CA) antibodies were used to detect the YAP
1 protein. Mouse GAPDH (1:2000, Sigma) and anti-
mouse (1:2000, Santa Cruz Biotechnology, Santa Cruz,
CA) antibodies were used to detect GAPDH.
TMA construction
TMA was constructed as the method described previously
[20]. In brief, formalin-fixed, paraffin-embedded tissue
blocks and the corresponding hematoxylin and eosin
(H&E)-stained slides were over laid for TMA sampling.
The slides were reviewed by a pathologist to determine
and mark out representative tumor areas. Duplicate of
0.6 mm diameter cylinders were punched from represen-
tative tumor areas of individual donor tissue block, and
re-embedded into a recipient paraffin block at a defined
position, using a tissue arraying instrument (Beecher
Instruments, SilverSpring, MD, USA). In our constructed
bladder tissue-TMA, three cores of a sample were selected
from each primary UCB and normal bladder tissue. Mul-
tiple sections (5 μm thick) were cut from the TMA block
and mounted on microscope slides. The TMA block
contained 213 UCBs and 86 specimens of normal bladder
tissues.
Immunohistochemistry (IHC)
The TMA slides were dried overnight at 37°C, de-
paraffinized in xylene, rehydrated through graded alco-
hol, immersed in 3% hydrogen peroxide for 15 minutes
to block endogenous peroxidase activity. And antigen-
retrieved by pressure cooking for 4 minutes in 10 nmol/l
citrate buffer (pH = 6.0) for YAP 1, or in ethylene-
diamine tetraacetic acid (EDTA) buffer (pH = 8.0) for
Ki-67. Then the slides were preincubated with 10% nor-
mal goat serum at room temperature for 30 minutes to
reduce nonspecific reaction. Subsequently, the slides
were incubated with mouse monoclonal anti-YAP 1
(Upstate Biotechnology, Lake Placid, NY) at a concen-
tration of 3 μg/ml and mouse monoclonal anti-Ki-67
(1:100, Zymed Laboratories Inc., South San Francisco,CA) overnight at 4°C. The slides were sequentially incu-
bated with a secondary antibody (Envision; Dako, Glostrup,
Denmark) for 2 hours and 30 minutes at room
temperature, and stained with DAB (3,3-diaminobenzidine).
Finally, the sections were counterstained with Mayer’s
hematoxylin, dehydrated, and mounted. A negative control
was obtained by replacing the primary antibody with a nor-
mal murine IgG. Known immunostaining positive slides
were used as positive controls.IHC evaluation
Two independent, blinded investigators examined all
tumor slides randomly. Five views were examined per
slide, and 100 cells were observed per view at ×400 mag-
nification. We graded the YAP 1 expression according to
the distribution, intensity, and percentage of positive
cells as described previously [14,21]. Absence of reactiv-
ity was graded as negative. With regard to cytoplasmic
distribution, weak cytoplasmic reactivity was considered
as low expression regardless of extent. Strong cytoplas-
mic reactivity with less than 50% positive cells was
graded as low expression. Otherwise it was graded as
high expression. With regard to nuclear distribution, nu-
clear expression in less than 10% of cells was graded as
low expression and nuclear expression in more than
10% cells was graded as high expression. Samples with
low or high YAP 1 staining were classified as YAP 1
positive expression. The status of nuclear expression of
Ki-67 was assessed by determining the percentage of
positive cells stained in each tissue section.
Statistical analysis
Statistical analysis was performed using the SPSS statistical
software package (standard version 13.0; SPSS, Chicago,
IL). The association of YAP 1 expression with UCB patient’s
clinic-pathological features and the molecular feature Ki-67
was assessed using the χ2-test. For survival analysis, we ana-
lyzed all UCB patients using Kaplan-Meier analysis. Log-
rank test was used to compare different survival curves.
Univariate and multivariate survival analyses were
performed using the Cox proportional hazards regression
model. Multivariate survival analysis was performed on all
parameters that were found to be significant on univariate
analysis. Differences were considered significant if the
P-value from a two-tailed test was <0.05.
Results
Expression of YAP 1 mRNA by qRT-PCR and YAP 1 protein
expression by Western blotting in paired bladder tissues
Our qRT-PCR results showed that YAP1 mRNA expres-
sion was upregulated in 12 of the 14 UCB samples com-
pared with the paired normal bladder tissues (Figure 1A).
Western blotting analyses also demonstrated upregulation
Figure 1 The expression of YAP 1 in UCB and normal bladder tissues. (A) Up-regulated expression of YAP 1 mRNA was examined by
qRT-PCR in 12/14 UCB cases, when compared with paired normal bladder tissues. Expression levels were normalized for β-actin. Error bars, SD
calculated from three parallel experiments. (B) Up-regulated expression of YAP 1 protein was detected by Western blotting in 11/14 UCB cases,
when compared with paired normal bladder tissues. Expression levels were normalized with GAPDH. (C-F) The expression of YAP 1 in UCB and
normal bladder tissues by IHC (100×). An UCB (case 39) tissue showed high expression of YAP 1, in which more than 90% of tumor cells were
positively stained by YAP 1 in the nucleus (C), while its paired normal bladder urothelial mucosal tissue was negatively stained by YAP 1 (D). High
expression of YAP 1 was observed in another UCB tissue (case 102), in which about 70% of tumor cells demonstrated a nuclear staining with a
lesser cytoplasmic staining of YAP 1 (E). An UCB (case 78) was examined low expression of YAP 1, in which less than 5% of tumor cells showed
nuclear staining of YAP 1 (F). An UCB (case 114) tissue showed high expression of YAP 1, in which more than 90% of tumor cells were positively
stained by YAP 1 in the cytoplasm (G).
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pared to their normal counterparts (Figure 1B).
Expression of YAP 1 in UCBs as determined by IHC
Next, expression and subcellular localization of the YAP 1
protein were determined by IHC in a TMA representative
of 213 cases of UCBs and 86 specimens of normal bladder
tissues. IHC staining showed that the YAP 1 protein was
mainly accumulated in the nucleus with a lesser cytoplas-
mic presence in bladder tissues (Figure 1C-1G). Based on
the criteria described before, positive expression of YAP
1 was found in 53.1% (113 ⁄ 213) of UCBs, and only 7.0%
(6 ⁄ 86) of normal bladder tissues.
Relationship between YAP 1 expression and UCB patients’
clinicopathologic variables
In our UCB cohort, the relationship between the expres-
sion of YAP 1 and patient clinical characteristics was
shown in Table 1. Positive expression of YAP 1 was found
to significantly correlate with poorer differentiation (P =0.001), higher T classification (P=0.010) and higher N clas-
sification (P = 0.028). No significant difference in YAP 1
expression was observed with age, gender, tumor size and
multiplicity (P > 0.05).
Relationship between clinicopathologic features, YAP 1
expression, and UCB patients’ survival: univariate survival
analysis
In univariate survival analyses, cumulative survival curves
were calculated according to the Kaplan-Meier method.
Differences in survival times were assessed using the log-
rank test. First, to confirm the representativeness of the
UCBs in our study, we analyzed established prognostic
predictors of patient survival. Kaplan-Meier analysis dem-
onstrated a significant impact of well-known clinical
pathological prognostic parameters, such as tumor grade,
pT status and pN status on patient survival (P < 0.05,
Table 2). Assessment of survival in total UCBs revealed
that positive expression of YAP 1 was correlated with
adverse survival of UCB patients (P < 0.001, Table 2,
Table 2 Univariate analysis of different prognostic factors
in 213 patients with urothelial carcinoma of bladder
Characteristics Total cases HR (95% CI) P value
Age (years) 0.118
≦62a 111 1
>62 102 1.598 (0.888-2.874)
Gender 0.054
Male 183 1
Female 30 0.241 (0.058-0.993)
Histological grade <0.001
G1 77 1
G2 69 2.627 (1.009-6.840)
G3 67 6.580 (2.701-16.030)
pT classification <0.001
pTa/pTis 89 1
pT1 42 11.433 (3.282-39.828)
pT2-4 82 14.407 (4.382-47.365)
pN classification <0.001
pN- 195 1
pN+ 18 9.310 (4.818-17.991)
Tumor size (cm) 0.003
≦2.4b 107 1
>2.4 106 2.572 (1.372-4.823)
Tumor multiplicity 0.939
Unifocal 102 1
Multifocal 111 0.978 (0.548-1.744)
YAP 1 <0.001
Negative 100 1
Positive 113 5.501 (2.460-12.304)
amedian age. bmean size. HR Hazards ratio. CI confidence interval.
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a prognostic factor in UCB patients having grades 2 and 3
tumors (P = 0.005 and 0.046, respectively, Figure 2,
Table 2), pT1 (P = 0.013), pT2-4 (P = 0.002) and pN- (P <
0.001) (Figure 2, Table 2). In addition, survival analysis
with regard to YAP 1 expression and a subset of pT2-4
UCB patients without lymph node metastasis (pT2-4/pN-,
n = 64) showed that expression of YAP1 was also a signifi-
cant prognostic factor (P = 0.004, Figure 2, Table 2).
Independent prognostic factors for UCB: multivariate cox
regression analysis
Since variables observed to have a prognostic influence
by univariate analysis may covariate, the expression of
YAP 1 and those clinicalopathological parameters that
were significant in univariate analysis (i.e., tumor grade,
pT status, pN status, tumor size) were further examined
in multivariate analysis. The results showed that the ex-
pression of YAP 1 was an independent prognostic factorfor overall patient survival (relative risk: 3.553, CI:
1.561-8.086, P = 0.003, Table 3). With regard to other
parameters, only tumor pT or pN status was shown to
be an independent prognostic factor (P<0.05, Table 3)
for overall survival.
Correlation between expressions of YAP1 and Ki-67
To address whether or not YAP 1 expression in UCB is
correlated with cell proliferation, the expression of Ki-67,
a widely used cellular proliferation marker, was investi-
gated using IHC in our UCB cohort. The expression level
of Ki-67 was assessed as a labeling index (LI), i.e., as the
percentage of Ki-67 positive cells in each tumor. In our
UCB cohorts, the mean LI value of Ki-67 for all 213 UCB
tumor samples was 31.2%, thus, the mean value of 31.2%
was used as a cutoff value to define low Ki-67 LI
(LI<31.2%) and high Ki-67 LI (LI≧31.2%). A significant
positive correlation between expression of YAP 1 and
Ki67 was evaluated in our UCB cohort, in which the fre-
quency of cases with high expression of Ki67 was signifi-
cantly larger in carcinomas with a positive expression of
YAP 1 (74/113 cases, 65.9%) than in those cases with a
negative expression of YAP 1 (46/100 cases, 46.0%; χ2 test,
P = 0.004, Table 4).
Discussion
Clinically, pTNM stage and tumor histopathological grade
are the best-established predictive factors for important
aspects affecting the prognosis of patients with UCB [22].
These two parameters, however, based on specific clinico-
pathologic features and extent of disease, may have
reached their limits in providing critical information influ-
encing patient prognosis and treatment strategies. Fur-
thermore, the outcome of patients with the same stage
and/or pathological grade of UCB is substantially different
and such large discrepancy has not been explored [23,24].
Thus, there is an urgent need for new objective strategies
that can effectively distinguish between patients with fa-
vorable and unfavorable prognosis.
YAP 1 is phosphorylated by the Hippo signaling path-
way, and is highly conserved along with other compo-
nents of this pathway; it is involved in regulating the
balance between cell proliferation and apoptosis to
maintain the steady-state of the cellular environment
[5,6,16]. Overexpression of YAP 1 has been implicated
in tumor progression in various human cancers, such as
liver, colon, ovarian and lung cancers [12,14,15,25].
These findings suggest a potential oncogenic role of
YAP1 in multiple human cancers. To date, however, the
expression status of YAP 1 in UCBs and its correlation
with the clinicopathological factors of this tumor has
not been elucidated. In the present study, we first exam-
ined the expression of YAP 1, both in mRNA and pro-
tein levels, in UCB and paired normal bladder tissues by
Figure 2 Kaplan-Meier survival analysis of YAP 1 expression in patients with UCB (log-rank test). Total, probability of survival of all patients
with UCB: negative expression (solid line), n = 100; positive expression (dashed line), n = 113. G1, probability of survival of G1 patients with UCB:
negative expression (solid line), n = 49; positive expression (dashed line), n = 28. G2, probability of survival of G2 patients with UCB: negative expression
(solid line), n = 29; positive expression (dashed line), n = 40. G3, probability of survival of G3 patients with UCB: negative expression (solid line), n = 22;
positive expression (dashed line), n = 45. pTa/pTis, probability of survival of pTa/pTis patients with UCB: negative expression (solid line), n = 52; positive
expression (dashed line), n = 37. pT1, probability of survival of pT1 patients with UCB: negative expression (solid line), n = 19; positive expression (dashed
line), n = 23. pT2-4, probability of survival of pT2-4 patients with UCB: negative expression (solid line), n = 29; positive expression (dashed line), n = 53.
pT2-4/pN-, probability of survival of pT2-4/pN- patients with UCB: negative expression (solid line), n = 25; positive expression (dashed line), n = 39. pN-,
probability of survival of pN- patients with UCB: ngative expression (solid line), n = 96; positive expression (dashed line), n = 99. pN+, probability of
survival of pN+ patients with UCB: negative expression (solid line), n = 4; positive expression (dashed line), n = 14.
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Table 3 Multivariate analysis on overall patient survival (Cox regerssion model)
Characteristic Hazards ratio 95% CI P value
YAP 1 (Negative vs Positive) 3.553 1.561-8.086 0.003
Histological grade (G1 vs G2 vs G3) 1.348 0.861-2.111 0.192
pT classification (pTa/pTis vs pT1 vs pT2-4) 1.668 1.042-2.669 0.033
pN classification (pN- vs pN+) 3.827 1.800-8.136 <0.001
Tumor size (cm) (≦2.4a vs >2.4) 1.900 0.987-3.657 0.055
amean size. CI confidence interval.
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showed that the mRNA and protein expressions of YAP
1 were frequently up-regulated in UCB tissues, when
compared with their paired normal bladder tissues.
Next, the expression dynamics of the YAP 1 protein was
examined by IHC, using a TMA containing a large co-
hort of UCB and normal bladder tissues. Our results
demonstrated that positive expression of YAP 1 was fre-
quently observed in UCB tissues. In contrast, only a
small population of normal bladder tissues showed posi-
tive staining for YAP 1. These findings suggest the pos-
sibility that up-regulated expression of YAP 1 may
provide a selective advantage in the UCB tumorigenic
processes.
In previous studies, YAP 1 expression was found to be
elevated and correlate closely with aggressive features,
and/or poor prognosis in many human cancers
[14-16,21,26-30]. A clinical study involving 177 hepato-
cellular carcinoma patients showed that YAP 1 could
serve as an independent predictor for hepatocellular
carcinoma-specific, disease-free survival and overall sur-
vival [15]. In 92 cases of non-small-cell lung carcinoma,
positive expression YAP 1 was observed in 66.3% of the
cases, and it was significantly correlated with lymph
node metastasis and later clinical stages, and it was a
poor prognostic predictor of the patients [21]. In our
study, further correlation analysis revealed that positive
expression of YAP 1 was correlated closely with tumors
poorer differentiation, higher pT and/or pN stages. Im-
portantly, positive expression of YAP 1 was a strong and
independent predictor of short overall survival of UCB
patients, as evidenced by the Kaplan-Meier curves and
multivariate Cox proportional hazards regression ana-
lysis. Furthermore, stratified survival analysis of UCB
histopathological grade and/or pTN stage showed thatTable 4 The correlation between expression of YAP 1 and
of Ki-67 in 213 cases of UCB
YAP 1 Cases
Labeling index (LI) of Ki-67 P
valueaLow no (%) High no (%)
Negative 100 54(54.0) 46(46.0)
0.004
Positive 113 39(34.5) 74(65.5)
aChi-square test. UCB urothelial carcinoma of the bladder.YAP 1 expression was closely correlated to survival of cer-
tain subsets of UCB patients, including patients having
grade 2/3 tumors and in pT1, pT2-4, pN- or pT2-4/ pN-
stage. Thus, YAP 1 expression appears to have the poten-
tial to indicate certain outcomes in UCB patients. The
examination of YAP 1 expression, therefore, could be used
as an additional tool in identifying patients at risk of UCB
progression, and it may also be useful in optimizing indi-
vidual UCB therapy management. These findings under-
score the potentially important role of YAP 1 in the
underlying biological mechanism involved in the develop-
ment and/or progression of UCB.
With respect to the function of the YAP 1 gene, as a
candidate oncogene, YAP 1 has been shown to be a potent
regulator of cell growth. Overexpression of YAP 1 in the
liver of transgenic mice could expand the liver mass from
5% of bodyweight to 25% and eventually lead to tumor
growth [17]. Moreover, YAP 1 overexpression stimulates
proliferation and increases the saturation cell density in
monolayer cultures of NIH-3T3 cells [16]. Furthermore,
overexpression of YAP 1 in NSCLC cell lines resulted in a
marked increase in the cell growth rate, and overcame
cell contact inhibition [21]. It is confirmed that YAP 1
overexpression in MCF10A cells triggered epithelial–
mesenchymal transition (EMT) [12], which is often associ-
ated with cancer cell invasion and metastasis. Although we
observed a positive association between YAP 1 expression
and Ki-67 expression (a marker for cell proliferation) in
our UCB cohort, the precise mechanisms that is ultimately
involved in the oncogenic processes of UCB remains to be
investigated. Nevertheless, our findings suggest the poten-
tial important role of YAP 1 in the control of UCB cell pro-
liferation, an activity that might be responsible, at least in
part, for the development and/or progression UCB.
Conclusions
In this study, we describe, for the first time, the mRNA
and protein expression patterns of YAP 1 in human UCB
tissues and in normal bladder tissues. Our results provide
a basis for the concept that increased expression of YAP 1
in UCB may be important in the acquisition of an aggres-
sive and/or poor prognostic phenotype. The results sug-
gest that the expression of YAP 1, as examined by IHC,
could be used as an important molecular marker for
Liu et al. BMC Cancer 2013, 13:349 Page 8 of 8
http://www.biomedcentral.com/1471-2407/13/349shortened survival time in patients with UCB, and it might
be helpful to render a more tailored treatment strategy in
this human cancer.
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